MCLA-117

Date Publication
Nov 09, 2016
MCLA-117, a CLEC12AXCD3 bispecific IgG targeting a leukemic stem cell antigen, induces T cell mediated AML blast lysis

Pieter Fokko van Loo, Henrike Veninga, Harry Dolstra, and Lex Bakker. Poster presented at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting, National Harbor, MD, USA.

MCLA-128

Date Publication
Oct 21, 2018
Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Maria Alsina, Andrea Varga, Alessio Amatu, Jan H.M. Schellens, Els Witteveen, Valentina Boni, Victor Moreno, Paolo Nuciforo, Aurelia de Vries Schultink, Kees Bol, Afrodite Lourbakos, Marina Magin Ferrer, and Ernesto Wasserman. Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.

May 14, 2018
Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade

Cecile A.W. Geuijen, Camilla De Nardis, David Maussang, Eric Rovers, Tristan Gallenne, Linda J.A. Hendriks, Therese Visser, Roy Nijhuis, Ton Logtenberg, John de Kruif, Piet Gros, and Mark Throsby. Cancer Cell, 33, 922-936 (2018).

May 05, 2018
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen, and Alwin D. R. Huitema. Investigational New Drugs, 36, 1006–1015 (2018).

Jun 02, 2017
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)

Maria Alsina, Valentina Boni, Aurelia de Vries Schultink, Victor Moreno, Kees Bol, Martine Westendorp, L. Andres Sirulnik, Josep Tabernero, and Emiliano Calvo. Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, USA.

Apr 01, 2017
The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis

David Maussang, Camilla De Nardis, Linda Hendriks, Carina Bartelink-Clements, Nellie Nieuwenhuizen, Eric Rovers, Tristan Gallenne, Robert Doornbos, Lex Bakker, Ton Logtenberg, John de Kruif, Piet Gros, Cecile Geuijen, and Mark Throsby. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.

MCLA-158

Date Publication
Apr 01, 2017
Identification and characterisation of MCLA-158 as an anti-EGFRxLGR5 bispecific antibody that potently inhibits patient-derived CRC organoid growth

Rob C. Roovers, Bram Herpers, Mark James, Berina Eppink, Carme Cortina, David Maussang-Detaille, Ingrid Kolfschoten, Sylvia F. Boy, Marc van de Wetering, Wim de Lau, Robert Doornbos, Carina Clements, Abdul Basmeleh, Willem Bartelink, Vanessa Zondag van de Zande, Kuan Yan, Lucia Salinaro, Lex Bakker, John de Kruif, Hans Clevers, Robert Vries, Eduard Batlle, Leo Price, and Mark Throsby. Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.

Technology

Date Publication
Jun 27, 2017
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1

Camilla De Nardis*, Linda J.A. Hendriks*, Emilie Poirier, Tudor Arvinte, Piet Gros, Alexander B.H. Bakker, and John de Kruif. Journal of Biological Chemistry, 292,  14706-14717 (2017).

Sep 26, 2016
Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity

Rinse Klooster, Cecile Geuijen, Renate den Blanken-Smit, Mireille Koenders, Annette Wensink, Eric Rovers, Hans van der Maaden, Steef Engels, Tristan Gallenne, Therese Visser, Carina Bartelink-Clements, Katinka van Zoest, Roy Nijhuis, Abdul Basmeleh, Willem Bartelink, Vanessa Zondag-van der Zande, Arjen Kramer, Linda Kaldenberg, Berina Eppink, Rob Roovers, Paul Tacken, Lex Bakker, Pieter Fokko van Loo, John de Kruif, and Mark Throsby. Poster presented at the International Congress on Immunotherapies in Cancer (ICIC) 2016 Annual Meeting, New York, NY, USA.

Nov 04, 2015
Generation of Wnt- and mitogenic receptor binding bispecific antibodies to target cancer stem cells

Berina Eppink, Rob Roovers, Bram Herpers, Wim de Lau, Carina Clements, Vanessa Zondag van der Zande, Abdul Basmeleh, Willem Bartelink, Marc van de Wetering, Robert Vries, Leo Price, John de Kruif, and Mark Throsby. Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.

Nov 11, 2013
Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry

Natalie J. Thompson, Linda J.A. Hendriks, John de Kruif, Mark Throsby, and Albert J.R. Heck. mAbs, 6, 197-203 (2013).

Aug 10, 2012
Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry

Sara Rosati, Natalie J. Thompson, Arjan Barendregt, Linda J. A. Hendriks, Alexander B. H. Bakker, John de Kruif, Mark Throsby, Esther van Duijn, and Albert J. R. Heck. Analytical Chemistry, 84, 7227–7232 (2012).

Jun 21, 2010
Generation of stable cell clones expressing mixtures of human antibodies

John de Kruif, Arjen Kramer, Roy Nijhuis, Vanessa van der Zande, Renate den Blanken, Carina Clements, Therese Visser, Rob Keehnen, Marcel den Hartog, Mark Throsby, and Ton Logtenberg. Biotechnology and Bioengineering, 106, 741-750 (2010).

Apr 03, 2009
Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous VH genes

John de Kruif, Arjen Kramer, Therèse Visser, Carina Clements, Roy Nijhuis, Freek Cox, Vanessa van der Zande, Renate Smit, Daniel Pinto, Mark Throsby, and Ton Logtenberg. Journal of Molecular Biology, 387, 548-558 (2009).